IGFBP2 and breast cancer: Furthermore, in comparisons between controls and each type of cancer, 5% of breast cancer patients (p = 0.032) and 40% of colorectal cancer patients (p < 0.001) had IGFBP-2 specific antibodies, compared to controls (Fig. 3B).